A Phase I, Open-label Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion, and to Assess the Absolute Bioavailability of AG-881 in Healthy Male Subjects Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881
Latest Information Update: 22 Apr 2021
At a glance
- Drugs Vorasidenib (Primary) ; Vorasidenib
- Indications Glioma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Agios Pharmaceuticals
Most Recent Events
- 17 Mar 2021 Results presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 25 Sep 2019 Status changed from recruiting to completed.
- 31 Jul 2019 Planned number of patients changed from 8 to 25.